142 related articles for article (PubMed ID: 15100333)
1. Unique strategy restores p53 function in mice.
Bucci M
J Natl Cancer Inst; 2004 Apr; 96(8):581. PubMed ID: 15100333
[No Abstract] [Full Text] [Related]
2. Therapeutic targeting of the p53 tumor suppressor gene.
Beaudry GA; Bertelsen AH; Sherman MI
Curr Opin Biotechnol; 1996 Dec; 7(6):592-600. PubMed ID: 8939636
[TBL] [Abstract][Full Text] [Related]
3. p53: a target for new anticancer drugs or a target for old drugs?
Brown R
Ann Oncol; 1993 Sep; 4(8):623-9. PubMed ID: 8240992
[No Abstract] [Full Text] [Related]
4. [p53 gene therapy for oral cancer].
Liu SX; Hu M
Zhonghua Kou Qiang Yi Xue Za Zhi; 2012 Sep; 47(9):569-72. PubMed ID: 23141735
[No Abstract] [Full Text] [Related]
5. Strategies for therapeutic targeting of the p53 pathway in cancer.
Wiman KG
Cell Death Differ; 2006 Jun; 13(6):921-6. PubMed ID: 16557267
[No Abstract] [Full Text] [Related]
6. [Can they heal p53].
Jeanteur P
Bull Cancer; 2000 Feb; 87(2):131-2. PubMed ID: 10705280
[No Abstract] [Full Text] [Related]
7. ONYX-015. Onyx Pharmaceuticals.
Cohen EE; Rudin CM
Curr Opin Investig Drugs; 2001 Dec; 2(12):1770-5. PubMed ID: 11892945
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of mutant p53: a new strategy for cancer therapy.
Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
Semin Cancer Biol; 1998; 8(5):369-78. PubMed ID: 10101802
[TBL] [Abstract][Full Text] [Related]
9. [Role of the p53 and bcl-2 genes in apoptosis and drug resistance of tumors].
Luk'ianova NIu; Kulik GI; Chehun VF
Vopr Onkol; 2000; 46(2):121-8. PubMed ID: 10853407
[No Abstract] [Full Text] [Related]
10. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1.
Li CJ; Wang C; Friedman DJ; Pardee AB
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5461-4. PubMed ID: 7777531
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
13. Designer molecule may lead to new treatments for ocular cancers.
Schultz J
J Natl Cancer Inst; 2002 Dec; 94(24):1827-9. PubMed ID: 12488472
[No Abstract] [Full Text] [Related]
14. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
16. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 proteins: between loss and gain of function.
Strano S; Dell'Orso S; Mongiovi AM; Monti O; Lapi E; Di Agostino S; Fontemaggi G; Blandino G
Head Neck; 2007 May; 29(5):488-96. PubMed ID: 17123310
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
19. Cancer gene therapy steadily advances.
Brower V
J Natl Cancer Inst; 2008 Sep; 100(18):1276-8. PubMed ID: 18780858
[No Abstract] [Full Text] [Related]
20. p53 and response to chemotherapy and radiotherapy.
Ruley HE
Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
